A
AdvanCell
Australia · Biotech · Healthtech
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
Business and product
Its platform links isotope production, automated manufacturing and clinical development. Lead program ADVC001 targets PSMA in metastatic prostate cancer and was in Phase 2 at the July financing announcement. It remains investigational.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series D | $315M | Abingworth — Role not disclosedAlly Bridge Group — Role not disclosedAlpha Wave — Role not disclosedBain Capital Life Sciences — Role not disclosedBrandon Capital — Role not disclosedCatalio Capital Management — Role not disclosedEli Lilly and Company — Role not disclosedEventide Asset Management — Role not disclosedFidelity Management & Research Company — Role not disclosedMorningside — Role not disclosedPiper Heartland — Role not disclosedProto Axiom — Role not disclosedSanofi Ventures — Role not disclosedSV Health Investors — Role not disclosedSymBiosis — Role not disclosedTenmile — Role not disclosedTime BioVentures — Role not disclosedT. Rowe Price Associates — Role not disclosedVelosity Capital — Role not disclosed |